Showing results (611-620 of 782) with videos related to

Sort By:
Pageof 79
Blood|August 5, 2004
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cellsPierfrancesco Tassone, Victor S Goldmacher, Paola Neri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström MacroglobulinemiaNa Li, Michael A Lopez, Maria Linares, et al.
The Journal of Clinical Investigation|March 21, 2018
Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppressionYawara Kawano, Oksana Zavidij, Jihye Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2010
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myelomaMaría Victoria Mateos, Maria Teresa Cibeira, Paul G Richardson, et al.
Blood|June 16, 2016
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Guang Yang, et al.
Blood|February 3, 2026
Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple MyelomaTing Du, Teng Fang, Sindhu C Pillai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2006
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321Bart Barlogie, Robert A Kyle, Kenneth C Anderson, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
Pageof 79